Dexamethasone: Oral aprepitant
, when given as a regimen of 125 mg with dexamethasone coadministered orally as 20 mg on Day 1, and oral aprepitant
when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate, by 2.
EMEND for Injection is an intravenous prodrug of the oral formulation of EMEND([R]) (aprepitant
), which means that when EMEND for Injection is administered, fosaprepitant is rapidly converted in the body to aprepitant
Contract award: tender for the supply of capsules aprepitant
negotiated procedure without call for competition (ddchpd.
LUGANO, Switzerland, April 2 /PRNewswire/ -- A new release of the NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology on Antiemesis recommends palonosetron as the "preferred" 5-HT3 antagonist in combination with aprepitant
and dexamethasone for prevention of emesis in highly emetic risk chemotherapy.
Significantly more patients in the group treated with the combination of palonosetron and aprepitant
had a complete response - defined as no emesis and no use of rescue medication - during the acute (0-24h; 92.
27) The physiological basis of this risk is demonstrated by the effectiveness of aprepitant
, an NK1/S-P inhibitor drug.
(Emend) is approved as an antiemetic agent for cancer patients on chemotherapy.
Compounds that block NK-1 receptors, including vofopitant, CP-122,721, CJ-11,794, fosaprepitant (L758,298), aprepitant
(MK-869), and casopitant, reduce emesis following cisplatin, ipecac, apomorphine, and radiation therapy (8), (11).
3] receptor antagonist, dexamethasone, and aprepitant
is useful for preventing nausea and vomiting in patients receiving cisplatin and other highly emetogenic agents (Eaton & Tipton, 2009).
(EMEND[R]) is a selective neurokinin-1 ([NK.
and administer two additional medications to prevent nausea: Zofran (ondansetron) and aprepitant
a 3-drug combination of 5HT3 serotonin receptor antagonist, dexamethasone and aprepitant
on day 1 for chemotherapy agents with a high emetic risk, e.